IP Library Granted Patent US 9,216,993
Granted Patent B2
US 9,216,993 · App. 14/203,233 · Granted Dec 22, 2015

Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Inventors: Jolanta Grembecka (Ann Arbor, MI); Tomasz Cierpicki (Ann Arbor, MI); Dmitry Borkin (Ann Arbor, MI); Jay L. Hess (Ann Arbor, MI); Duxin Sun (Ann Arbor, MI); Xiaoqin Li (Ann Arbor, MI)
Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
C07D495/04C07D495/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,216,993
App. No.
14/203,233
Granted
Dec 22, 2015
Kind
B2
Abstract

The present disclosure relates generally to thienopyrimidine and thienopyridine compounds and methods of use thereof. In particular embodiments, the present disclosure provides compositions comprising thienopyrimidine and thienopyridine compounds of Formula 4: and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins.

Claims (66)

1. A compound of Formula 4:

or a pharmaceutically acceptable salt thereof, wherein

each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is independently H, alkyl, substituted alkyl, alcohol, ether, amine, halogen, ketone, amide, cyano, sulfonylmethane, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

wherein R 6 is present at one or more positions of the indole;

Y is N, C—H, or

R a is alkyl, heteroalkyl, alkyl-substituted aryl, substituted alkyl, alcohol, ether, amino, cyano, aldehyde, heterocycloalkyl, or aromatic group; and

L is alkylene, oxalkylene, or absent; wherein when L is absent the bonds attached to L do not exist.

2. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound is selected from:

3. A method for the treatment of leukemia comprising administering a compound of claim 1 to a subject suffering from leukemia.

4. The method of claim 3 , wherein said leukemia comprises AML or ALL.

5. A method of inhibiting the interaction of MLL and menin comprising administering a compound of claim 1 to a sample comprising MLL or MLL fusion protein and menin.

6. The compound or pharmaceutically acceptable salt of claim 1 , wherein Y is N.

7. The compound or pharmaceutically acceptable salt of claim 6 , wherein L is absent.

8. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is alkyl or substituted alkyl.

9. The compound or pharmaceutically acceptable salt of claim 8 , wherein R 1 is a halogen-substituted alkyl group.

10. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 2 is H, alkyl, substituted alkyl, halogen, alcohol, ether, or amine.

11. The compound or pharmaceutically acceptable salt of claim 10 , wherein R 2 is H.

12. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 3 is H alkyl, amine, alcohol, heterocycloalkyl, or substituted alkyl.

13. The compound or pharmaceutically acceptable salt of claim 12 , wherein R 3 is H.

14. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 4 is H alkyl, substituted alkyl, alcohol, or amine.

15. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 5 is H, alkyl, substituted alkyl, or alcohol.

16. The compound or pharmaceutically acceptable salt of claim 1 , wherein each R 6 is independently alkyl, substituted alkyl, alcohol, ether, halogen, amine, or cyano.

17. The compound or pharmaceutically acceptable salt of claim 16 , comprising an R 6 connected to position 3, 4, or 6 of the indole.

18. The compound or pharmaceutically acceptable salt of claim 16 , comprising more than one R 6 .

19. The compound or pharmaceutically acceptable salt of claim 16 , comprising an R 6 at a position of the phenyl portion of the indole.

20. The compound or pharmaceutically acceptable salt of claim 16 , comprising an R 6 at a position of the pyrrole portion of the indole.

21. The compound or pharmaceutically acceptable salt of claim 16 , comprising an R 6 at a position of the phenyl portion of the indole and an R 6 at a position of the pyrrole portion of the indole.

22. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 7 is H, alkyl, substituted alkyl, alcohol, ether, heteroaryl, substituted heteroaryl, amide, or amine.

23. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 8 is H, alkyl, substituted alkyl, alcohol, heteroaryl, substituted heteroaryl, cyano, amine, amide, sulfonylmethane, or ketone.

24. The compound or pharmaceutically acceptable salt of claim 23 , wherein R 8 is cyano.

25. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 6 , R 7 , or R 8 is cyano halo, alkyl, substituted alkyl, alcohol heteroaryl, substituted heteroaryl, amine, amide heterocycle ether, or ketone.

26. The compound or pharmaceutically acceptable salt of claim 1 , wherein L is absent.

27. The compound of claim 1 , represented by the structure of Formula 7:

or a pharmaceutically acceptable salt thereof, wherein

each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is independently H, alkyl, substituted alkyl, alcohol, ether, amine, halogen, ketone, amide, cyano, sulfonylmethane, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, or substituted heterocycloalkyl;

wherein R 6 is present at one or more positions of the indole;

Y is N, or C—R a ;

R a is alkyl, heteroalkyl, alkyl-substituted aryl, substituted alkyl, alcohol, ether, amino, cyano, aldehyde, heterocycloalkyl or aromatic group; and

L is alkylene, oxalkylene, or absent; wherein when L is absent the bonds attached to L do not exist.

28. The compound or pharmaceutically acceptable salt of claim 27 , wherein Y is N.

29. The compound or pharmaceutically acceptable salt of claim 28 , wherein L is absent.

30. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 1 is alkyl or substituted alkyl.

31. The compound or pharmaceutically acceptable salt of claim 30 , wherein R 1 is a halogen-substituted alkyl group.

32. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 2 is H, alkyl, substituted alkyl, halogen, alcohol, or amine.

33. The compound or pharmaceutically acceptable salt of claim 32 , wherein R 2 is H.

34. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 3 is H, alkyl, amine, alcohol, heterocycloalkyl, or substituted alkyl.

35. The compound or pharmaceutically acceptable salt of claim 34 , wherein R 3 is H.

36. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 4 is H, alkyl, substituted alkyl, alcohol, or amine.

37. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 5 is H, alkyl, substituted alkyl, or alcohol.

38. The compound or pharmaceutically acceptable salt of claim 27 , wherein each R 6 is independently alkyl, substituted alkyl, alcohol, ether, halogen, amine, or cyano.

39. The compound or pharmaceutically acceptable salt of claim 38 , comprising an R 6 connected to position 3, 4, or 6 of the indole.

40. The compound or pharmaceutically acceptable salt of claim 38 , comprising more than one R 6 .

41. The compound or pharmaceutically acceptable salt of claim 38 , comprising an R 6 at a position of the phenyl portion of the indole.

42. The compound or pharmaceutically acceptable salt of claim 38 , comprising an R 6 at a position of the pyrrole portion of the indole.

43. The compound or pharmaceutically acceptable salt of claim 38 , comprising an R 6 at a position of the phenyl portion of the indole and an R 6 at a position of the pyrrole portion of the indole.

44. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 7 is H, alkyl, substituted alkyl, alcohol, heteroaryl, substituted heteroaryl, amide, or amine.

45. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 8 is H, alkyl, substituted alkyl, alcohol, heteroaryl, heteroaryl, cyano, amine, amide, sulfonylmethane, or ketone.

46. The compound or pharmaceutically acceptable salt of claim 45 , wherein R 8 is cyano.

47. The compound or pharmaceutically acceptable salt of claim 27 , wherein R 6 , R 7 , or R 8 is cyano, halo, alkyl, substituted alkyl, alcohol heteroaryl, substituted heteroaryl, amine, amide heterocycle, ether, or ketone.

48. The compound or pharmaceutically acceptable salt of claim 27 , wherein L is absent.

49. The compound or pharmaceutically acceptable salt of claim 16 , wherein each R 6 is independently alkyl, haloalkane, halogen, alcohol, ether, or amine.

50. The compound or pharmaceutically acceptable salt of claim 22 , wherein R 7 is H, alkyl, haloalkane, alcohol, (CH 2 ) n —OR, (CH 2 ) n —R, (CH 2 ) m —O—(CH 2 ) m —R, heteroaryl, or substituted heteroaryl, wherein n is 1-10, m is 1-10, and R is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.

51. The compound or pharmaceutically acceptable salt of claim 22 , wherein R 7 is H, alkyl or substituted alkyl.

52. The compound or pharmaceutically acceptable salt of claim 38 , wherein each R 6 is independently alkyl, haloalkane, halogen, alcohol, ether, or amine.

53. The compound or pharmaceutically acceptable salt of claim 44 , wherein R 7 is H, alkyl, haloalkane, alcohol, (CH 2 ) n —OR, (CH 2 ) n —R, (CH 2 ) m —O—(CH 2 ) m —R, heteroaryl, or substituted heteroaryl, wherein n is 1-10, m is 1-10, and R is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.

54. The compound or pharmaceutically acceptable salt of claim 44 , wherein R 7 is H, alkyl or substituted alkyl.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019
From: NANOSYN
To: THE LEUKEMIA & LYMPHOMA SOCIETY, INC.
Reel/Frame 048829/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2019
From: THE LEUKEMIA & LYMPHOMA SOCIETY, INC.
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 048829/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2019
From: IBRAHIM, MOHAMAD; PLEKHOV, ARTEM; KIMBROUGH, THOMAS; GREENMAN, KEVIN; MIROSHNIKOVA, OLGA; KAMAL, ZEESHAN
To: NANOSYN
Reel/Frame 048814/0419 →
CONFIRMATORY LICENSE Recorded Jan 26, 2017
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041494/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2014
From: GREMBECKA, JOLANTA; CIERPICKI, TOMASZ; BORKIN, DMITRY; HESS, JAY L.; SUN, DUXIN; LI, XIAOQIN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 032976/0735 →
Continuity (2)
Provisional Application 61780099 · Mar 13, 2013
Related Publication 20140275070A1 · Sep 18, 2014